Dana-Farber Cancer Institute

The first day of poster presentations at
#ESMO25 featured some of our expert's insights into topics from the impact of genomic alterations to results from a phase Ill trial of immunotherapy responders.

Robert Haddad, MD, and Ravindra Uppaluri, MD, PhD, join an interactive case discussion on state-of-the-art management of resectable locally advanced head and neck cancer, exploring how novel strategies are being integrated into patient care. #ESMO25

@stolaney1.bsky.social shares an emerging role of antibody-drug conjugates in first-line treatment of metastatic triple-negative breast cancer, highlighting new possibilities for earlier use of these therapies. #ESMO25

Pasi A. Jänne, MD, MPH, is back on stage sharing advancing targeted therapy research for patients with KRAS G12C-mutated NSCLC, highlighting emerging strategies and growing momentum in lung cancer treatment. #ESMO25

Pasi A. Jänne, MD, MPH discussing strategies to target oncogenes in NSCLC, with a focus on preventing and treating resistance to improve outcomes for patients with lung cancer. #ESMO25

Erica Mayer, MD, MPH, presents the first results from a evERA BC trial which studies a new oral therapy, giredestrant, combined with everolimus for people with advanced ER+/HER2– breast cancer who have already tried CDK4/6 treatments. #ESMO25

#ESMO25 continues today! Follow along here and with @danafarbernews.bsky.social as we learn and explore the latest in oncology care and research or join us at our upcoming discussions and poster presentations: bit.ly/4nfWCyL

@stolaney1.bsky.social joins the #ESMO25 roundtable with other leading oncology experts for a dynamic session on strategic sequencing in HER2+ metastatic breast cancer.

Dr. Pasi Jänne of Dana-Farber Cancer Institutes presents at #ESMO25.

Lung cancer research at #ESMO25: Chemotherapy combo boosts overall survival in patients with EGFR-mutant non-small cell lung cancer. @danafarber.bsky.social's Dr. Pasi Jänne presents the complete data from phase 3 FLAURA2 study.

Press release ➡️bit.ly/47oV0hd

Pasi A. Jänne, MD, MPH, presents exploratory results from the FLAURA2 study, examining outcomes for patients with advanced EGFR-mutated lung cancer treated with osimertinib, with or without chemotherapy, as first-line therapy. #ESMO25

We’re excited to be at #ESMO25! Follow along here and with @danafarbernews.bsky.social as we learn and explore the latest in oncology care and research or join us at our upcoming discussions and poster presentations: bit.ly/4nfWCyL

Paul Richardson, MD

Congratulations to Paul Richardson, MD, recognized by the Lymphoma, Leukemia, & Myeloma Congress with the Joseph Michaeli Award for Outstanding Contributions to Myeloma. His leadership helped introduce cornerstone treatments for multiple myeloma, each of which has kept the field at the cutting edge.

Jessica A. Pollard, MD

Join us in congratulating Jessica A. Pollard, MD, on receiving the 2025 Healing Hero of Excellence in Pediatric Oncology award from Kids Beating Cancer, recognizing her compassionate care and dedication to advancing childhood cancer cures.

Can Immunotherapy be Combined with Chemotherapy to Fight Cancer? Researchers are exploring how immunotherapy and chemotherapy, two types of cancer therapies, may be used together.

Can chemotherapy and immunotherapy work better together?

For some cancers, the answer is yes. Research has shown that combining these treatments, called chemoimmunotherapy, can lead to better outcomes than either treatment alone.

Learn how these therapies work together: bit.ly/3HcPYdF

Weight Loss Trial Reports Success for Breast Cancer Patients at One Year Mark | Dana-Farber Cancer Institute Breast cancer patients who participated in a remote weight loss intervention program lost an average of 4.7 percent of their baseline body weight after one year, while those in the education only control group gained an average 1 percent of their baseline weight, according to a new report from Dana-Farber Cancer Institute investigators.

Breast cancer patients who participated in a weight loss intervention program lost an average of 4.7% of their baseline body weight after one year, while those in the education only control group gained an average 1% of their baseline weight.

Learn more about the findings: bit.ly/3Kpesld

Breast Cancer Awareness Month Boston 25 Weather The Local Life(Opens in new window) Share your pics(Opens in new window)

Sara Tolaney, MD, of @danafarber.bsky.social joined @boston25news.com to discuss the latest in breast cancer treatment, trends and screening.

➡️ bit.ly/3WvxUze

Blavatnik National Awards

Blavatnik National Awards

Blavatnik National Awards

Blavatnik National Awards

Congratulations to Philip J. Kranzusch, Ph.D., Professor of Cancer Immunology and Virology, who was one of three scientists awarded top honors at the 2025 Blavatnik National Awards for Young Scientists.

Watch to learn more about his work: bit.ly/4pZUDkF

U.S. News & World Report – Best Children's Hospitals – Cancer

We are proud to announce that U.S. News & World Report has recognized Dana-Farber/Boston Children's (@bostonchildrens.bsky.social) Cancer and Blood Disorders Center as the #3 pediatric cancer program in the nation in its 2025-26 Best Children's Hospitals report.

Learn more: bit.ly/4o7ApUc

New Strategy for Small Cell Lung Cancer Treatment Emerges from Dana-Farber Science | Dana-Farber Cancer Institute New research from Dana-Farber Cancer Institute shows that a new class of drug results in cancer cell death in cancers, such as small cell lung cancer, with a disabled quality control cell cycle checkpoint known as the G1/S checkpoint. The evidence gathered in the Oser Lab at Dana-Farber supports testing of the strategy in humans. A phase 1 clinical trial is now open nationwide for patients with small cell lung cancer, triple negative breast cancer, and other cancers.

Researchers have provided the mechanistic and preclinical evidence needed to support a clinical trial of a new class of drugs called direct cyclin inhibitors in patients with a range of cancers. Learn more: bit.ly/46OtMPQ

New Diagnostic Tool Developed at Dana-Farber Revolutionizes Acute Leukemia Diagnosis | Dana-Farber Cancer Institute Researchers at Dana-Farber Cancer Institute have developed a groundbreaking diagnostic tool that could transform the way acute leukemia is identified and treated. The tool, called MARLIN (Methylation- and AI-guided Rapid Leukemia Subtype Inference), uses DNA methylation patterns and machine learning to classify acute leukemia with speed and accuracy. This tool has the potential to significantly improve patient care by allowing faster and more precise treatment decisions.

Dana-Farber researchers have developed a groundbreaking diagnostic tool that could transform the way acute leukemia is identified and treated. The tool uses DNA methylation patterns and machine learning to classify acute leukemia with speed and accuracy.

Learn more: bit.ly/46CrT8y

Cancer AI Alliance unveils first collaborative AI platform for cancer research - Cancer AI Alliance Secure, scalable, multi-cloud platform using federated learning aims to accelerate cancer discoveries and treatments

We're proud to join members of the Cancer AI Alliance in launching the first collaborative AI platform for cancer research. The platform enables researchers to train AI models that learn from millions of clinical data points to help drive new discoveries and clinical advances.

OncLive State of the Science Summit | Gastrointestinal Cancers | Boston, MA | October 29, 2025 OncLive® State of the Science Summit™ (SOSS) are in-person meetings designed for academic & community-based physicians and health care professionals that provide education on the science driving updates in cancer management and the associated clinical benefits for patients. SOSS attendees will improve their knowledge of novel treatment approaches and reinforce their confidence in applying state-of-the-art treatment strategies.

Join event chair James Cleary, MD, PhD, on October 29 for the 2025 @onclive.bsky.social Gastrointestinal Cancer State of the Science Summit. This event brings oncology professionals together to share and learn from each other about the latest advancements in cancer diagnosis and treatment.

Anthony Letai, MD, PhD

Congratulations to Anthony Letai, MD, PhD, on being named the new director of the National Cancer Institute. His appointment is a testament to our continuing commitment to innovation and collaboration.

Learn more: bit.ly/4pRWiZy

132 patient safety experts to know | 2025 - Becker's Hospital Review | Healthcare News & Analysis The following patient safety experts are unwavering champions for patient harm reduction, disease management and disaster preparedness. Representing various roles across hospitals, health systems and healthcare companies, they all share a common goal of keeping patients safe and satisfied. Safety is the driving mission for these leaders, guiding them to constantly pioneer new approaches, refine […]

Hakim Lakhani has been named one of Becker's Healthcare's Patient Safety Experts to Know 2025. His expertise is instrumental in advancing patient safety and improving care delivery.

Please join us in congratulating him on this recognition. View the full list here: bit.ly/3WbQHPT

Immunotherapy for Lymphoma, Multiple Myeloma, and Leukemia: What's New? Immunotherapy for cancer has made some of its biggest inroads against hematologic malignancies such as leukemia and lymphoma, with treatments such as checkpoint inhibitors and CAR T-cell therapies producing long-lasting remissions in some patients.

Our experts are at the forefront of research in immunotherapies for blood cancer — from checkpoint inhibitors to CAR T-cell and bispecific antibody trials now shaping treatment. Learn more: bit.ly/3I6dGsz

Benjamin L. Ebert, MD, PhD

Benjamin L. Ebert, MD, PhD, and Mariella Filbin, MD, PhD

This weekend, faculty members of Dana-Farber/Boston Children's (@bostonchildrens.bsky.social) Cancer and Blood Disorders Center are presenting at the @theaacr.bsky.social Pediatric Special Conference in Cancer.

Oncology News Politics Tech Fact Check Personal Finance Automotive Sports Better Workplaces

We’re honored to be recognized as World’s Best Specialized Hospitals in oncology by @newsweek.com. This recognition highlights our commitment to excellence in oncology care and our dedication to providing world-class treatment for our patients. bit.ly/4ntQ1BM

Dana-Farber Cancer Institute

Through a first-of-its-kind program, @danafarber.bsky.social and Northeastern University are training the next generation of oncology nurses while setting a national standard for academic-clinical collaboration to meet urgent healthcare demands. #DanaFarber #NortheasternUniversity

➡️ bit.ly/48wd0Hp

Future of Medicine Summit

“The New Face of Cancer” @danafarber.bsky.social’s Kimmie Ng, MD, MPH, joined Trisha Pasricha, MD, MPH, and Shuji Ogino, MD, PhD, at @bostonglobe.com's Future of Medicine Summit, discussing the alarming rise of cancer in adults younger than 55, moderated by @leungboston.bsky.social